Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Biomolecules ; 14(2)2024 Feb 11.
Article in English | MEDLINE | ID: mdl-38397448

ABSTRACT

Niemann-Pick Disease (NPD) is a rare autosomal recessive disease belonging to lysosomal storage disorders. Three types of NPD have been described: NPD type A, B, and C. NPD type A and B are caused by mutations in the gene SMPD1 coding for sphingomyelin phosphodiesterase 1, with a consequent lack of acid sphingomyelinase activity. These diseases have been thus classified as acid sphingomyelinase deficiencies (ASMDs). NPD type C is a neurologic disorder due to mutations in the genes NPC1 or NPC2, causing a defect of cholesterol trafficking and esterification. Although all three types of NPD can manifest with pulmonary involvement, lung disease occurs more frequently in NPD type B, typically with interstitial lung disease, recurrent pulmonary infections, and respiratory failure. In this sense, bronchoscopy with broncho-alveolar lavage or biopsy together with high-resolution computed tomography are fundamental diagnostic tools. Although several efforts have been made to find an effective therapy for NPD, to date, only limited therapeutic options are available. Enzyme replacement therapy with Olipudase α is the first and only approved disease-modifying therapy for patients with ASMD. A lung transplant and hematopoietic stem cell transplantation are also described for ASMD in the literature. The only approved disease-modifying therapy in NPD type C is miglustat, a substrate-reduction treatment. The aim of this review was to delineate a state of the art on the genetic basis and lung involvement in NPD, focusing on clinical manifestations, radiologic and histopathologic characteristics of the disease, and available therapeutic options, with a gaze on future therapeutic strategies.


Subject(s)
Lung Diseases , Niemann-Pick Disease, Type A , Niemann-Pick Disease, Type B , Niemann-Pick Diseases , Humans , Niemann-Pick Disease, Type A/genetics , Niemann-Pick Disease, Type A/metabolism , Niemann-Pick Disease, Type A/therapy , Niemann-Pick Disease, Type B/genetics , Niemann-Pick Disease, Type B/therapy , Niemann-Pick Diseases/genetics , Niemann-Pick Diseases/therapy , Lung Diseases/genetics , Lung Diseases/therapy , Mutation , Rare Diseases , Lung/metabolism
2.
Sci Transl Med ; 11(506)2019 08 21.
Article in English | MEDLINE | ID: mdl-31434754

ABSTRACT

Niemann-Pick disease type A (NPD-A) is a lysosomal storage disorder characterized by neurodegeneration and early death. It is caused by loss-of-function mutations in the gene encoding for acid sphingomyelinase (ASM), which hydrolyzes sphingomyelin into ceramide. Here, we evaluated the safety of cerebellomedullary (CM) cistern injection of adeno-associated viral vector serotype 9 encoding human ASM (AAV9-hASM) in nonhuman primates (NHP). We also evaluated its therapeutic benefit in a mouse model of the disease (ASM-KO mice). We found that CM injection in NHP resulted in widespread transgene expression within brain and spinal cord cells without signs of toxicity. CM injection in the ASM-KO mouse model resulted in hASM expression in cerebrospinal fluid and in different brain areas without triggering an inflammatory response. In contrast, direct cerebellar injection of AAV9-hASM triggered immune response. We also identified a minimally effective therapeutic dose for CM injection of AAV9-hASM in mice. Two months after administration, the treatment prevented motor and memory impairment, sphingomyelin (SM) accumulation, lysosomal enlargement, and neuronal death in ASM-KO mice. ASM activity was also detected in plasma from AAV9-hASM CM-injected ASM-KO mice, along with reduced SM amount and decreased inflammation in the liver. Our results support CM injection for future AAV9-based clinical trials in NPD-A as well as other lysosomal storage brain disorders.


Subject(s)
Dependovirus/metabolism , Genetic Therapy , Niemann-Pick Disease, Type A/genetics , Niemann-Pick Disease, Type A/therapy , Serogroup , Animals , Brain/metabolism , Brain/pathology , Humans , Inflammation/pathology , Injections , Liver/pathology , Mice, Knockout , Motor Activity , Primates , Sphingomyelin Phosphodiesterase/administration & dosage , Sphingomyelin Phosphodiesterase/blood , Sphingomyelin Phosphodiesterase/genetics , Transgenes
3.
Mol Genet Metab ; 126(2): 98-105, 2019 02.
Article in English | MEDLINE | ID: mdl-30514648

ABSTRACT

BACKGROUND: Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. OBJECTIVES: To provide a contemporary guide of clinical assessments for disease monitoring and symptom management across the spectrum of ASMD phenotypes. METHODS: An international group of ASMD experts in various research and clinical fields used an evidence-informed consensus process to identify optimal assessments, interventions, and lifestyle modifications. RESULTS: Clinical assessment strategies for major organ system involvement, including liver, spleen, cardiovascular, pulmonary, and neurological/developmental are described, as well as symptomatic treatments, interventions, and/or life style modifications that may lessen disease impact. CONCLUSIONS: There is currently no disease-specific treatment for ASMD, although enzyme replacement therapy with a recombinant human ASM (olipudase alfa) is in clinical development. Current monitoring addresses symptoms and multisystem involvement. Recommended interventions and lifestyle modifications are designed to address morbidity and disease complications and improve patient quality of life. While infantile neurovisceral ASMD is uniformly fatal in early childhood, patients with chronic visceral and chronic neurovisceral ASMD require appropriate management throughout childhood and adulthood by an interdisciplinary clinical team.


Subject(s)
Disease Management , Monitoring, Physiologic/methods , Niemann-Pick Disease, Type A/therapy , Practice Guidelines as Topic , Clinical Trials as Topic , Enzyme Replacement Therapy , Humans , Monitoring, Physiologic/statistics & numerical data , Mutation , Niemann-Pick Disease, Type A/diagnosis , Phenotype , Quality of Life , Risk Reduction Behavior
4.
Stem Cells Transl Med ; 5(12): 1644-1655, 2016 12.
Article in English | MEDLINE | ID: mdl-27484861

ABSTRACT

: Niemann-Pick disease type A (NPA) is a lysosomal storage disease caused by mutations in the SMPD1 gene that encodes acid sphingomyelinase (ASM). Deficiency in ASM function results in lysosomal accumulation of sphingomyelin and neurodegeneration. Currently, there is no effective treatment for NPA. To accelerate drug discovery for treatment of NPA, we generated induced pluripotent stem cells from two patient dermal fibroblast lines and differentiated them into neural stem cells. The NPA neural stem cells exhibit a disease phenotype of lysosomal sphingomyelin accumulation and enlarged lysosomes. By using this disease model, we also evaluated three compounds that reportedly reduced lysosomal lipid accumulation in Niemann-Pick disease type C as well as enzyme replacement therapy with ASM. We found that α-tocopherol, δ-tocopherol, hydroxypropyl-ß-cyclodextrin, and ASM reduced sphingomyelin accumulation and enlarged lysosomes in NPA neural stem cells. Therefore, the NPA neural stem cells possess the characteristic NPA disease phenotype that can be ameliorated by tocopherols, cyclodextrin, and ASM. Our results demonstrate the efficacies of cyclodextrin and tocopherols in the NPA cell-based model. Our data also indicate that the NPA neural stem cells can be used as a new cell-based disease model for further study of disease pathophysiology and for high-throughput screening to identify new lead compounds for drug development. SIGNIFICANCE: Currently, there is no effective treatment for Niemann-Pick disease type A (NPA). To accelerate drug discovery for treatment of NPA, NPA-induced pluripotent stem cells were generated from patient dermal fibroblasts and differentiated into neural stem cells. By using the differentiated NPA neuronal cells as a cell-based disease model system, α-tocopherol, δ-tocopherol, and hydroxypropyl-ß-cyclodextrin significantly reduced sphingomyelin accumulation in these NPA neuronal cells. Therefore, this cell-based NPA model can be used for further study of disease pathophysiology and for high-throughput screening of compound libraries to identify lead compounds for drug development.


Subject(s)
Induced Pluripotent Stem Cells/cytology , Models, Biological , Niemann-Pick Disease, Type A/pathology , Niemann-Pick Disease, Type A/therapy , 2-Hydroxypropyl-beta-cyclodextrin , Cell Differentiation/drug effects , Cell Line , Fibroblasts/drug effects , Fibroblasts/pathology , Fibroblasts/ultrastructure , Humans , Induced Pluripotent Stem Cells/drug effects , Induced Pluripotent Stem Cells/ultrastructure , Lysosomes/drug effects , Lysosomes/metabolism , Lysosomes/ultrastructure , Neural Stem Cells/drug effects , Neural Stem Cells/pathology , Neural Stem Cells/ultrastructure , Sphingomyelin Phosphodiesterase/metabolism , Sphingomyelins/metabolism , Tocopherols/pharmacology , alpha-Tocopherol/pharmacology , beta-Cyclodextrins/pharmacology
5.
Pediatr Endocrinol Rev ; 13 Suppl 1: 674-81, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27491215

ABSTRACT

Two distinct metabolic abnormalities are included under the eponym Niemann-Pick disease (NPD). The first is due to the deficient activity of the enzyme acid sphingomyelinase (ASM). Patients with ASM deficiency are classified as having types A and B Niemann-Pick disease (NPD). Type A NPD patients exhibit hepatosplenomegaly, frequent pulmonary infections, and profound central nervous system involvement in infancy. They rarely survive beyond two years of age. Type B patients also have hepatosplenomegaly and progressive alterations of their lungs, but there are usually no central nervous system signs. The age of onset and rate of disease progression varies greatly among type B patients, and they frequently live into adulthood. Recently, patients with phenotypes intermediate between types A and B NPD also have been identified. These individuals represent the expected continuum caused by inheriting different mutations in the ASM gene (SMPD1). Patients in the second category are designated as having type C NPD. Impaired intracellular trafficking of cholesterol causes type C NPD, and two distinct gene defects have been found. In this chapter only types A and B NPD will be discussed.


Subject(s)
Bone Marrow Transplantation , Enzyme Replacement Therapy , Genetic Therapy , Niemann-Pick Disease, Type A/therapy , Niemann-Pick Disease, Type B/therapy , Sphingomyelin Phosphodiesterase/therapeutic use , Age of Onset , Animals , Central Nervous System Diseases/physiopathology , Disease Models, Animal , Disease Progression , Hepatomegaly , Humans , Lung Diseases/physiopathology , Mutation , Niemann-Pick Disease, Type A/genetics , Niemann-Pick Disease, Type A/physiopathology , Niemann-Pick Disease, Type B/genetics , Niemann-Pick Disease, Type B/physiopathology , Phenotype , Sphingomyelin Phosphodiesterase/genetics , Splenomegaly
6.
Best Pract Res Clin Endocrinol Metab ; 29(2): 237-47, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25987176

ABSTRACT

Two distinct metabolic abnormalities are encompassed under the eponym Niemann-Pick disease (NPD). The first is due to the deficient activity of the enzyme acid sphingomyelinase (ASM). Patients with ASM deficiency are classified as having types A and B Niemann-Pick disease (NPD). Type A NPD patients exhibit hepatosplenomegaly in infancy and profound central nervous system involvement. They rarely survive beyond two years of age. Type B patients also have hepatosplenomegaly and pathologic alterations of their lungs, but there are usually no central nervous system signs. The age of onset and rate of disease progression varies greatly among type B patients, and they frequently live into adulthood. Recently, patients with phenotypes intermediate between types A and B NPD also have been identified. These individuals represent the expected continuum caused by inheriting different mutations in the ASM gene (SMPD1). Patients in the second NPD category are designated as having types C and D NPD. These patients may have mild hepatosplenomegaly, but the central nervous system is profoundly affected. Impaired intracellular trafficking of cholesterol causes types C and D NPD, and two distinct gene defects have been found. In this chapter only types A and B NPD will be discussed.


Subject(s)
Central Nervous System Diseases/etiology , Hepatomegaly/etiology , Lung Diseases/etiology , Niemann-Pick Disease, Type A/complications , Niemann-Pick Disease, Type B/complications , Splenomegaly/etiology , Bone Marrow Transplantation , Enzyme Replacement Therapy , Humans , Niemann-Pick Disease, Type A/metabolism , Niemann-Pick Disease, Type A/therapy , Niemann-Pick Disease, Type B/metabolism , Niemann-Pick Disease, Type B/therapy , Phenotype , Sphingomyelin Phosphodiesterase/genetics
7.
Cell Death Differ ; 21(6): 864-75, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24488099

ABSTRACT

Niemann Pick disease type A (NPA), which is caused by loss of function mutations in the acid sphingomyelinase (ASM) gene, is a lysosomal storage disorder leading to neurodegeneration. Yet, lysosomal dysfunction and its consequences in the disease are poorly characterized. Here we show that undegraded molecules build up in neurons of acid sphingomyelinase knockout mice and in fibroblasts from NPA patients in which autophagolysosomes accumulate. The latter is not due to alterations in autophagy initiation or autophagosome-lysosome fusion but because of inefficient autophago-lysosomal clearance. This, in turn, can be explained by lysosomal membrane permeabilization leading to cytosolic release of Cathepsin B. High sphingomyelin (SM) levels account for these effects as they can be induced in control cells on addition of the lipid and reverted on SM-lowering strategies in ASM-deficient cells. These results unveil a relevant role for SM in autophagy modulation and characterize autophagy anomalies in NPA, opening new perspectives for therapeutic interventions.


Subject(s)
Autophagy/genetics , Lysosomes/metabolism , Niemann-Pick Disease, Type A/genetics , Sphingomyelins/metabolism , Animals , Cathepsin B/metabolism , Humans , Lysosomes/pathology , Mice , Niemann-Pick Disease, Type A/pathology , Niemann-Pick Disease, Type A/therapy , Sphingomyelin Phosphodiesterase/metabolism
8.
Mol Ther ; 20(10): 1893-901, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22828503

ABSTRACT

Niemann-Pick disease Type A (NPA) is a neuronopathic lysosomal storage disease (LSD) caused by the loss of acid sphingomyelinase (ASM). The goals of the current study are to ascertain the levels of human ASM that are efficacious in ASM knockout (ASMKO) mice, and determine whether these levels can be attained in non-human primates (NHPs) using a multiple parenchymal injection strategy. Intracranial injections of different doses of AAV1-hASM in ASMKO mice demonstrated that only a small amount of enzyme (<0.5 mg hASM/g tissue) was sufficient to increase survival, and that increasing the amount of hASM did not enhance this survival benefit until a new threshold level of >10 mg hASM/g tissue was reached. In monkeys, injection of 12 tracts of AAV1-hASM resulted in efficacious levels of enzyme in broad regions of the brain that was aided, in part, by axonal transport of adeno-associated virus (AAV) and movement through the perivascular space. This study demonstrates that a combination cortical, subcortical, and cerebellar injection protocol could provide therapeutic levels of hASM to regions of the NHP brain that are highly affected in NPA patients. The information from this study might help design new AAV-mediated enzyme replacement protocols for NPA and other neuronopathic LSDs in future clinical trials.


Subject(s)
Genetic Therapy , Niemann-Pick Disease, Type A/therapy , Sphingomyelin Phosphodiesterase/deficiency , Animals , Brain/enzymology , Dependovirus/genetics , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Genetic Vectors/genetics , Injections , Macaca fascicularis , Male , Mice , Mice, Knockout , Niemann-Pick Disease, Type A/pathology , Primates/metabolism , Sphingomyelin Phosphodiesterase/genetics , Sphingomyelin Phosphodiesterase/metabolism
9.
Mol Ther ; 20(9): 1713-23, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22735381

ABSTRACT

Central nervous system (CNS)-directed gene therapy with recombinant adeno-associated virus (AAV) vectors has been used effectively to slow disease course in mouse models of several neurodegenerative diseases. However, these vectors were typically tested in mice without prior exposure to the virus, an immunological scenario unlikely to be duplicated in human patients. Here, we examined the impact of pre-existing immunity on AAV-mediated gene delivery to the CNS of normal and diseased mice. Antibody levels in brain tissue were determined to be 0.6% of the levels found in systemic circulation. As expected, transgene expression in brains of mice with relatively high serum antibody titers was reduced by 59-95%. However, transduction activity was unaffected in mice that harbored more clinically relevant antibody levels. Moreover, we also showed that markers of neuroinflammation (GFAP, Iba1, and CD3) and histopathology (hematoxylin and eosin (H&E)) were not enhanced in immune-primed mice (regardless of pre-existing antibody levels). Importantly, we also demonstrated in a mouse model of Niemann Pick Type A (NPA) disease that pre-existing immunity did not preclude either gene transfer to the CNS or alleviation of disease-associated neuropathology. These findings support the continued development of AAV-based therapies for the treatment of neurological disorders.


Subject(s)
Antibodies, Viral/immunology , Brain/immunology , Dependovirus/genetics , Genetic Therapy/methods , Niemann-Pick Disease, Type A/therapy , Adult , Animals , Antibodies, Viral/metabolism , Biomarkers/metabolism , Brain/metabolism , Dependovirus/immunology , Disease Models, Animal , Gene Transfer Techniques , Genetic Vectors , Humans , Immunization , Mice , Niemann-Pick Disease, Type A/genetics , Niemann-Pick Disease, Type A/immunology , Niemann-Pick Disease, Type A/metabolism , Transgenes
11.
J Inherit Metab Dis ; 30(6): 987, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17960492

ABSTRACT

Niemann-Pick disease type A (NP-A; OMIM 257200) is an autosomal recessive lysosomal storage disorder caused by deficiency of acid sphingomyelinase and resulting in accumulation of sphingomyelin, unesterified cholesterol, and other complex lipids in many tissues. It is characterized by failure to thrive, hepatosplenomegaly, and a rapidly progressive neurodegenerative course culminating in death by 3 years of age. There is no known effective treatment. We report the case of a prenatally diagnosed girl who underwent cord blood stem cell transplantation (CBSCT) at 3 months of age. She was neurologically intact at the time of CBSCT. Hepatosplenomegaly, was detected at 6 weeks of age; the splenomegaly resolved following CBSCT. Recovery was complicated by graft-versus-host disease. She subsequently developed and continues to show marked global developmental delay, generalized hypotonia, and signs of neurological regression, despite continued engraftment. Bilateral cherry red spots were detected at 10 months of age, 7 months post-CBSCT. Although she is doing better than her affected brother, she shows little overall benefit from CBSCT.


Subject(s)
Fetal Blood/cytology , Niemann-Pick Disease, Type A/metabolism , Niemann-Pick Disease, Type A/therapy , Stem Cell Transplantation/methods , Developmental Disabilities , Female , Humans , Infant , Liver Diseases/pathology , Male , Nervous System Diseases/etiology , Nervous System Diseases/pathology , Splenomegaly/diagnosis , Splenomegaly/therapy , Treatment Outcome
12.
J Inherit Metab Dis ; 30(5): 654-63, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17632693

ABSTRACT

Patients with types A and B Niemann-Pick disease (NPD) have an inherited deficiency of acid sphingomyelinase (ASM) activity. The clinical spectrum of this disorder ranges from the infantile, neurological form that results in death by 3 years of age (type A NPD) to the non-neurological form (type B NPD) that is compatible with survival into adulthood. Intermediate cases also have been reported, and the disease is best thought of as a single entity with a spectrum of phenotypes. ASM deficiency is panethnic, but appears to be more frequent in individuals of Middle Eastern and North African descent. Current estimates of the disease incidence range from approximately 0.5 to 1 per 100,000 births. However, these approximations likely under estimate the true frequency of the disorder since they are based solely on cases referred to biochemical testing laboratories for enzymatic confirmation. The gene encoding ASM (SMPD1) has been studied extensively; it resides within an imprinted region on chromosome 11, and is preferentially expressed from the maternal chromosome. Over 100 SMPD1 mutations causing ASM-deficient NPD have been described, and some useful genotype-phenotype correlations have been made. Based on these findings, DNA-based carrier screening has been implemented in the Ashkenazi Jewish community. ASM 'knockout' mouse models also have been constructed and used to investigate disease pathogenesis and treatment. Based on these studies in the mouse model, an enzyme replacement therapy clinical trial has recently begun in adult patients with non-neurological ASM-deficient NPD.


Subject(s)
Niemann-Pick Disease, Type A , Niemann-Pick Disease, Type B , Sphingomyelin Phosphodiesterase/deficiency , Animals , Bone Marrow Transplantation , Bronchoalveolar Lavage , Disease Models, Animal , Enzyme Inhibitors/therapeutic use , Genetic Testing , Genetic Therapy , Genotype , Humans , Mice , Mice, Knockout , Mutation , Niemann-Pick Disease, Type A/diagnosis , Niemann-Pick Disease, Type A/enzymology , Niemann-Pick Disease, Type A/ethnology , Niemann-Pick Disease, Type A/genetics , Niemann-Pick Disease, Type A/therapy , Niemann-Pick Disease, Type B/diagnosis , Niemann-Pick Disease, Type B/enzymology , Niemann-Pick Disease, Type B/ethnology , Niemann-Pick Disease, Type B/genetics , Niemann-Pick Disease, Type B/therapy , Phenotype , Recombinant Proteins/therapeutic use , Sphingomyelin Phosphodiesterase/genetics , Sphingomyelin Phosphodiesterase/therapeutic use , Splenectomy
SELECTION OF CITATIONS
SEARCH DETAIL
...